摘要
目的了解EMA-CO方案治疗耐药妊娠滋养细胞肿瘤(GTN)的疗效。方法回顾性总结在我院2005年10月至2015年10月期间收治的21例应用EMA-CO方案治疗对一线5-FU单药化疗方案耐药GTN患者的临床疗效及不良反应。结果 EMA-CO方案对于耐药GTN的治愈率可达90.48%,不良反应主要是骨髓抑制、消化道反应和肝功轻度损害,其中Ⅲ度骨髓抑制占9.57%,Ⅳ度骨髓抑制占3.19%,Ⅰ~Ⅱ度消化道反应占39.36%,Ⅰ~Ⅱ度肝功能损害占13.83%,其余未发生严重并发症。结论 EMA-CO方案的疗效肯定,不良反应轻,患者易于接受,可作为耐药GTN的首选化疗方案。
Objective To investigate the efficacy of EMA-CO regimen in the treatment of drug-resistant gestational trophoblastic tumor（GTN）. Methods The clinical efficacy and side effects of EMA-CO regimen in the treatment of GTN resistant pa- tients with first-line 5-FU single drug chemotherapy regimen were retrospectively reviewed in 21 cases treated in Sichuan Provincial People＇s Hospital from October 2005 to October 2015. Results The cure rate of EMA-CO regimen for resistant GTN was up to 90. 48%. The main adverse reactions were bone marrow suppression, gastrointestinal reactions and mild liver damage. Among them, bone marrow suppression of degree Ⅲ accounted for 9.57%, bone marrow suppression of degree IV accounted for 3.19%, digestive tract reaction of degree Ⅰ-Ⅱ accounted for 39. 36% ,liver function damage of degree Ⅰ-Ⅱ accounted for 13.83% ,and the rest of patients did not have serious complications. Conclusion The EMA-CO regimen has definite efficacy, mild side effects, and is easy to accept as a preferred chemotherapy regimen for drug-resistant GTN
出处
《四川医学》
CAS
2017年第9期1063-1065,共3页
Sichuan Medical Journal
